Treatment of chlamydial infections

Bibliography

• Centers for Disease Control and Prevention. 2010 Sexually transmitted diseases treatment guidelines. MMWR 2010;59(RR-12):1-110
   PubMedGoogle Scholar
• Hammerschlag MR, Kohlhoff SA, Darville T. Chlamydia pneumoniae and Chlamydia trachomatis. In: Fratamico PM, Smith JL, Brogden KA, editors. Sequelae and long-term consequences of infectious diseases. American Society for Microbiology; Washington, DC: 2009. p. 27-52
   Google Scholar
• Rockey DD, Lenart J, Stephens RS. Genome sequencing and our understanding of chlamydiae. Infect Immun 2000;68:5473-9
   PubMed Web of Science ®Google Scholar
• Dreses-Werringloer U, Padubrin I, Jurgens-Saathoff B, Persistence of chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob Agents Chemother 2000;44:3288-97
   PubMed Web of Science ®Google Scholar
• Eickhoff M, Thalmann J, Hess S, Host cell responses to chlamydia pneumoniae in gamma interferon-induced persistence overlap those of productive infection and are linked to genes involved in apoptosis, cell cycle, and metabolism. Infect Immun 2007;75:2853-63
   PubMed Web of Science ®Google Scholar
• Harper A, Pogson CI, Jones ML, Chlamydial development is adversely affected by minor changes in amino acid supply, blood plasma amino acids levels, and glucose deprivation. Infect Immun 2000;68:1457-64
   PubMed Web of Science ®Google Scholar
• Hogan RJ, Mathews SA, Mukhopadhyay S, Chlamydial persistence: beyond the biphasic paradigm. Infect Immun 2004;72:1843-55
   PubMed Web of Science ®Google Scholar
• Mpiga P, Ravaoarinoro M. Chlamydia trachomatis persistence: an update. Microbiol Res 2006;161:9-19
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Miller RD, Sullivan ED, Protein expression profiles of Chlamydia pneumoniae in models of persistence versus those of heat shock stress response. Infect Immun 2006;74:3853-63
   PubMed Web of Science ®Google Scholar
• Polkinghorne A, Hogan RJ, Vaughn L, Differential expression of chlamydial signal transduction genes in normal and interferon gamma-induced persistent Chlamydophila pneumoniae infections. Microbes Infect 2006;8:61-72
   PubMed Web of Science ®Google Scholar
• Hogan R, Mathews S, Kutlin A, Differential expression of genes encoding membrane proteins between acute and continuous Chlamydia pneumoniae infections. Microbes Pathog 2003;34:11-16
   PubMedGoogle Scholar
• Kutlin A, Roblin PM, Hammerschlag MR. Effect of prolonged treatment with azithromycin, clarithromycin and levofloxacin on Chlamydia pneumoniae in a continuous infection model. Antimicrob Agents Chemother 2002;46:409-12
   PubMed Web of Science ®Google Scholar
• Senn L, Hammerschlag MR, Greub G. Therapeutic approaches to Chlamydia infections. Expert Opin Pharmacother 2005;6:1-10
   PubMedGoogle Scholar
• Suchland RJ, Geisler WM, Stamm WE. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother 2002;47:636-42
   Google Scholar
• Sandoz KM, Rockey DD. Antibiotic resistance in Chlamydiae. Future Microbiol 2010;5:1427-42
   PubMed Web of Science ®Google Scholar
• Ghuysen JM, Goffin C. Lack of cell wall peptidoglycan versus penicillin sensitivity: new insights into the chlamydial anomaly. Antimicrob Agents Chemother 1999;43:2339-44
   PubMed Web of Science ®Google Scholar
• Stamm WE. Chlamydia trachomatis infections in the adult. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Cory L, Cohen M, Watts H, editors. Sexually Transmitted Diseases. 4th edition. McGraw Hill; New York: 2008. p. 575-94
   Google Scholar
• Dessus-Babus S, Bebear CM, Charron A, Sequencing of gyrase and topoisomerase IV quinolones sequence-determining regions of Chlamydia trachomatis and characterization of quinolones resistant mutants obtained in vitro. Antimicrob Agents Chemother 1998;42:2474-81
   PubMedGoogle Scholar
• Morrissey I, Salman H, Bakker S, Serial passage of Chlamydia spp. in subinhibitory fluoroquinolone concentrations. J Antimicrob Chemother 2002;49:757-61
   PubMed Web of Science ®Google Scholar
• Kutlin A, Kohlhoff S, Roblin P, Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis. Antimicrob Agents Chemother 2005;49:903-7
   PubMed Web of Science ®Google Scholar
• Jones RB, Van Der Pol B, Martin DH, Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis 1990;162:1309-15
   PubMed Web of Science ®Google Scholar
• Somani J, Bhullar VB, Workowski KA, Multiple drug- resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000;181:1421-7
   PubMed Web of Science ®Google Scholar
• Misyurina OY, Chipitsyna EV, Finashutina YP, Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides. Antimicrob Agents Chemother 2004;48:1347-9
   PubMed Web of Science ®Google Scholar
• Bhengraj AR, Vardhan H, Srivastava P, Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India. Chemotherapy 2010;56:371-7
   PubMed Web of Science ®Google Scholar
• Bhengraj AR, Srivastava P, Mittal A. Lack of mutation in macrolide resistance genes in Chlamydia trachomatis clinical isolates with decreased susceptibility to azithromycin. Int J Antimicrob Agents 2011;38:178-9
   PubMedGoogle Scholar
• Block S, Hedrick J, Hammerschlag MR, Mycoplasma pneumoniae and Chlamydia pneumoniae in community acquired pneumonia in children: comparative safety and efficacy of clarithromycin and erythromycin suspensions. Pediatr Infect Dis J 1995;14:471-7
   PubMed Web of Science ®Google Scholar
• Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithromycin and susceptibility to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community acquired pneumonia. Antimicrob Agents Chemother 1998;42:194-6
   PubMed Web of Science ®Google Scholar
• Harris J-A, Kolokathis A, Campbell M, Safety and efficacy of azithromycin in the treatment of community acquired pneumonia in children. Pediatr Infect Dis J 1998;17:865-71
   PubMed Web of Science ®Google Scholar
• Hammerschlag MR, Roblin PM. Microbiologic efficacy of levofloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother 2000;44:1409
   PubMed Web of Science ®Google Scholar
• Hammerschlag MR, Roblin PM. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents 2000;15:149-52
   PubMed Web of Science ®Google Scholar
• Roblin PM, Montalban G, Hammerschlag MR. Susceptibility to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother 1994;38:1588-9
   PubMed Web of Science ®Google Scholar
• Riska PF, Kutlin A, Ajiboye P, Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. Antimicrob Agents Chemother 2004;48:3586-690
   PubMed Web of Science ®Google Scholar
• Rupp J, Gebert A, Solbach W, Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae. Antimicrob Agents Chemother 2005;49:406-7
   PubMedGoogle Scholar
• Kutlin A, Roblin PM, Hammerschlag MR. Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model. J Antimicrob Chemother 2002;49:763-7
   PubMedGoogle Scholar
• Batteiger BE, Tu W, Ofner S, Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 2010;201:42-51
   PubMed Web of Science ®Google Scholar
• Wang SA, Papp JR, Stamm WE, Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report. J Infect Dis 2005;191:917-23
   PubMed Web of Science ®Google Scholar
• Rice RJ, Bhullar V, Mitchell SH, Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease. Antimicrob Agents Chemother 1995;39:760-2
   PubMed Web of Science ®Google Scholar
• Samra Z, Rosenberg S, Soffer Y, In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis 2001;39:177-9
   PubMed Web of Science ®Google Scholar
• Hong KC, Schachter J, Moncada J, Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. Emerg Infect Dis 2009;15:1088-90
   PubMed Web of Science ®Google Scholar
• Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis 2007;44:568-76
   PubMed Web of Science ®Google Scholar
• Lau C-Y, Qureshi AK. Azithromycin versus doxycycline for genital Chlamydia infections. A meta-analysis of randomized clinical trials. Sex Transm Dis 2002;29:497-502
   PubMed Web of Science ®Google Scholar
• Judlin P, Liao Q, Liu Z, Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010;117:1475-84
   PubMed Web of Science ®Google Scholar
• Gaydos CA, Crotchfelt KA, Howell MR, Molecular amplification assays to detect chlamydial infections in urine specimens from high school female students ant to monitor the persistence of chlamydial DNA after therapy. J Infect Dis 1998;177:417-24
   PubMed Web of Science ®Google Scholar
• Renault CA, Israelski DM, Levy V, Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. Sex Health 2011;8:69-73
   PubMed Web of Science ®Google Scholar
• Pitsouni E, Iavazzo C, Athtanasiou S, Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomized controlled trials. Int J Antimicrob Agents 2007;30:213-21
   PubMed Web of Science ®Google Scholar
• de Vries HJC, Smelov V, Middleburg JG, Delayed microbial cure of lymphogranuloma venereum proctitis with doxycycline treatment. Clin Infect Dis 2009;48:e53-6
   Google Scholar
• Mechai F, de Barbeyrac D, Aoun O, Doxycycline failure in lymphogranuloma venereum. Sex Transm Infect 2010;86:278-9
   PubMedGoogle Scholar
• Nieuwenhuis RF, Ossewaarde JM, van der Meijden WI, Unusual presentation of early lymphogranuloma venereum in an HIV-1 infected patient: effective treatment with 1 g azithromycin. Sex Transm Infect 2003;79:453-5
   PubMedGoogle Scholar
• Mandell LA, Wunderink RG, Anzueto A, Infectious disease Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-71
   PubMed Web of Science ®Google Scholar
• Vergis EN, Indorf A, File TM, Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients. Arch Intern Med 2000;160:1294-300
   PubMedGoogle Scholar
• Pletz MW, Rohde G, Schutte H, Epidemiology and aetiology of community-acquired pneumonia. Dtsch Med Wochenschr 2011;136:775-80
   PubMedGoogle Scholar
• Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics against atypical pathogens in nonsevere community-acquired pneumonia: meta-analysis. BMJ 2005;330:456
   PubMed Web of Science ®Google Scholar
• Wubbel L, Muniz L, Ahmed A, Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J 1999;18:98-104
   PubMed Web of Science ®Google Scholar
• Sutherland ER, King TS, Icitovic N, A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010;126:747-53
   PubMed Web of Science ®Google Scholar
• Johnston SL, Blasi F, Black PN, The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006;354:1589-600
   PubMed Web of Science ®Google Scholar
• Roblin PM, Kohlhoff SA, Parker C, In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. Antimicrob Agents Chemother 2010;54:1358-9
   PubMed Web of Science ®Google Scholar
• Jones RN, Biedenbach DJ, Roblin PM, Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. Antimicrob Agents Chemother 2010;54:4518-19
   PubMedGoogle Scholar
• Hammerschlag MR, Sharma R. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert Opin Investig Drugs 2008;17:387-400
   PubMed Web of Science ®Google Scholar
• Stamm WE, Batteiger BE, McCormack WM, A randomized double-blind study comparing single-dose rifalazil with single dose azithromycin for empirical treatment of nongonococal urethritis in men. Sex Transm Dis 2007;34:545-52
   PubMedGoogle Scholar
• Hammerschlag MR, Kohlhoff SA, Apfalter P. Chlamydophila (Chlamydia) pneumoniae. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 7th edition. Elsevier, Inc.; Philadephia, PA: 2009. p. 2467-75
   Google Scholar